Sun Pharmaceuticals Financial Statement

Total profit show a positive increase from 18% in 2013 to 31% in 2015, far reaching the brothers’ preference of $1.1 M in 2015, Appendix 3 showed $1.4 M net profit

Initially Sun Pharma started its operations with two eastern states i.e. West Bengal and Bihar with only 5 products which were used to treat psychiatric ailments. Sun Pharma’s business is split into US Generics, Indian Branded Generics and Active Pharmaceutical Ingredients. The brands are specifically targeted towards therapy areas which include cardiology, respiratory, gastroenterology, psychiatry, diabetology and neurology. They are involved in making speciality APIs which includes steroids, anti cancers, peptides and hormones. Dosage forms and API’s are manufactured at around 20 plants

Five of the top ten pharmaceutical companies are located in the United States and the other five are European companies, all of these companies combined, employ approximately 787,000 people. The ranking of the following pharmaceutical companies are based on

Looking back at the statement of financial positon for 2013, 2014 and 2015 shows increases each year in the revenue. Investments over this period have increased by 2 million. Equipment and improvement expenses have gone down. In 2013 the expense was over 300k. 2014 and 2015 were much smaller around 10k. 2016 jumped up to just over 200k. This shows that attention is being paid to improving the office and equipment and staying up to date with technology.

The company mission statement indicates that it envisions becoming a principal pharmaceutical manufacturing corporation with a special dedication to advance innovation in medicine with the

revenue increased by 13.1% from $513m in 2011 to $580.22m in 2012, its operating income decreased by 7.8% from

Joseph Dumit announces how pharmaceutical organizations are exploiting us shoppers, control with showcasing procedures and making it so we return for more solution. These brings up the issue do pharmaceuticals have our best enthusiasm to make us more beneficial or are they just in it for the cash. Dumit states that in 2011 pharmaceuticals made about $880 billion dollars and is relied upon to grow 5% consistently later on (18). Dumit thinks something is wrong with these organizations and takes a gander at the ceaseless development in medications, conclusion, expenses and weakness, he adopted the strategy to take after cash and following associations between the benefits of organizations and ailment extension (10).

1. Evidence from case: Exhibit 2, Revenues and Income from operations shows an increase from 10.6% in 2012- 19.5% in 2016. (Page C-100)

This illustrates that the company's money has been increasing but not much as earning money

It is evident that there was a proportionately significant 71% increase in net profit in sales ratio in comparison to the 40% increase in revenue and the costs remaining was steady connected with the increased revenues delivering much higher profit. There was also an increase in the overall amount of the current assets that therefore covered the liabilities in the current status.

we saw increase in sales from 11070 to 12223.8, net earnings also boosted from 382.9 to 519.3. Similarly, cash flow from operating activities also increased by 136 million dollars. At the same time, net earnings rose up to 523 million dollars in 2015. On the other hand, total assets upgraded from 4817.4 to

We analyzed the Indian Pharmaceutical industry on these five forces and the findings of industry competitiveness and profitability are written under the relevant competitive forces.

BioCryst began in 1986 and by 2008 was pronounced as one of the fastest growing pharmaceutical companies in the US (Debutts 2008). BioCryst does not produce the vast number of drugs and hold as many patents as many of the giants in the US pharmaceutical industry, but its products are highly specialized and in high demand (Mani 2006).This is the key advantage that BioCryst has in the US market, and would also form the central strategy in an Indian expansion project. BioCryst's primary drug line is Permavir Outpatient Flu, which is currently the only drug approved for use in the US. However, BioCryst currently has several other drugs in various stages of development that are expected to be approved for use in the US in time (BioCryst 2012). These are:

The company’s aim is to become world’s most broad- based pharmaceutical companies by manufacturing quality medicines, which regulates the demand of the developed world. Within a short span of time, Maple built a reputable image of excellence by manufacturing quality products and step towards accomplishing its vision of becoming a mainstream Pharmaceutical Company.

Drug portfolio management is one of the most important determinants of long-term prosperity of research-oriented pharmaceutical companies.